Efgartigimod for generalized myasthenia gravis: a comprehensive review of clinical evidence and future perspectives - Top-Institutions - MDSpire

Efgartigimod for generalized myasthenia gravis: a comprehensive review of clinical evidence and future perspectives

  • By

  • Lingyu Jiang

  • Jiaping Wei

  • Junqi Qin

  • Jing He

  • Shengjing Liang

  • Jianwei Huang

  • Yunzhi Ma

  • Yifan Zhou

  • Yonglong Zhong

  • June 10, 2026

  • 0 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    University of North Carolina at Chapel Hill School of Medicine
    University of North Carolina at Chapel Hill School of Medicine

    Chapel Hill, North Carolina

    Key Differentiators

    • Neurology

  • #2

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, Ohio

    Key Differentiators

    • Neurology

  • #3

    Peking University First Hospital
    Peking University First Hospital

    Beijing, China

    Key Differentiators

    • Neurology

  • #4

    First Affiliated Hospital of Guangzhou University of Chinese Medicine
    First Affiliated Hospital of Guangzhou University of Chinese Medicine

    Guangzhou, China

    Key Differentiators

    • Neurology

  • #5

    Charité—University Hospital Berlin
    Charité—University Hospital Berlin

    Berlin, Germany

    Key Differentiators

    • Neurology

Original Source(s)

Efgartigimod for generalized myasthenia gravis: a comprehensive review of clinical evidence and future perspectives

  • by Lingyu Jiang, Jiaping Wei, Junqi Qin, Jing He, Shengjing Liang, Jianwei Huang, Yunzhi Ma, Yifan Zhou, Yonglong Zhong

  • June 10, 2026

Related Content

Altered GABA and secondary bile acids in Guillain-Barré syndrome: association with gut dysbiosis

Combined SSTR2-targeted Analogue with 177Lu-DOTATATE radionuclide and octreotide therapy for refractory meningioma: a case report

Case Report: Ofatumumab for the treatment of refractory anti-NMDAR-positive autoimmune encephalitis